scholarly journals Pathogenesis of COVID-19 associated mucormycosis (CAM) in India: probing the triggering factors

Author(s):  
Gururaj Arakeri ◽  
Shreyas Patil ◽  
Vishal Rao ◽  
Rui Amaral Mendes ◽  
Rachel S Oeppen ◽  
...  
Keyword(s):  
2018 ◽  
Vol 24 (15) ◽  
pp. 1639-1651 ◽  
Author(s):  
Xian-ling Qian ◽  
Jun Li ◽  
Ran Wei ◽  
Hui Lin ◽  
Li-xia Xiong

Background: Anticancer chemotherapeutics have a lot of problems via conventional Drug Delivery Systems (DDSs), including non-specificity, burst release, severe side-effects, and damage to normal cells. Owing to its potential to circumventing these problems, nanotechnology has gained increasing attention in targeted tumor therapy. Chemotherapeutic drugs or genes encapsulated in nanoparticles could be used to target therapies to the tumor site in three ways: “passive”, “active”, and “smart” targeting. Objective: To summarize the mechanisms of various internal and external “smart” stimulating factors on the basis of findings from in vivo and in vitro studies. Method: A thorough search of PubMed was conducted in order to identify the majority of trials, studies and novel articles related to the subject. Results: Activated by internal triggering factors (pH, redox, enzyme, hypoxia, etc.) or external triggering factors (temperature, light of different wavelengths, ultrasound, magnetic fields, etc.), “smart” DDSs exhibit targeted delivery to the tumor site, and controlled release of chemotherapeutic drugs or genes. Conclusion: In this review article, we summarize and classify the internal and external triggering mechanism of “smart” nanoparticle-based DDSs in targeted tumor therapy, and the most recent research advances are illustrated for better understanding.


Landslides ◽  
2021 ◽  
Author(s):  
Bastian Morales ◽  
Elizabet Lizama ◽  
Marcelo A. Somos-Valenzuela ◽  
Mario Lillo-Saavedra ◽  
Ningsheng Chen ◽  
...  

2014 ◽  
Vol 12 (6) ◽  
pp. 519-529 ◽  
Author(s):  
Vera Mahler ◽  
Thomas Diepgen ◽  
Christoph Skudlik ◽  
Detlef Becker ◽  
Heinrich Dickel ◽  
...  
Keyword(s):  

2012 ◽  
Vol 132 (5) ◽  
pp. 1392-1400 ◽  
Author(s):  
Terhi Savinko ◽  
Sampsa Matikainen ◽  
Ulpu Saarialho-Kere ◽  
Maili Lehto ◽  
Guoying Wang ◽  
...  

2013 ◽  
Vol 88 (4) ◽  
pp. 578-584 ◽  
Author(s):  
Amanda Rodrigues Miranda ◽  
Ana Paula Fusel de Ue ◽  
Dominique Vilarinho Sabbag ◽  
Wellington de Jesus Furlani ◽  
Patricia Karla de Souza ◽  
...  

In this article, three cases of hereditary angioedema (HAE) type III (estrogen-dependent or with normal C1 inhibitor) are reported. The HAE was initially described in women of the same family in association with high-leveled estrogenic conditions such as the use of oral contraceptives and pregnancy. There is no change in the C1 inhibitor as happens in other types of hereditary angioedema, and mutations are observed in the encoding gene of the XII factor of coagulation in several patients. The current diagnosis is mainly clinical and treatment consists in the suspension of the triggering factors and control of acute symptoms. A brief review of physiopathology, clinical features, genetic alterations and treatment are also presented.


Sign in / Sign up

Export Citation Format

Share Document